Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders

2 years ago

Company Announcement, Helsinki, 31 March 2023 at 1 PM (EEST) Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders…

Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates

2 years ago

SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a…

Mendus AB: Change in number of shares and votes in Mendus AB (publ)

2 years ago

During March, the number of shares and votes in Mendus AB (publ) has changed as a result of 1,137,790 new…

Study shows significant improvement in bladder emptying with Coloplast’s Luja™ compared to competitor catheter

2 years ago

Luja Coloplast's intermittent male catheter LujaStudy results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete…

Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F

2 years ago

Saint-Herblain (France), March 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the…

Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD

2 years ago

Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD Pixium Vision to receive interactive communication…

BioSenic provides Financial Update and Financial Calendar 2023

2 years ago

INSIDE INFORMATION Mont-Saint-Guibert, Belgium, March 31, 2023, 7am CET - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company…

Jamieson Wellness Inc. Announces Filing of Management Information Circular for Annual and Special Meeting of Shareholders

2 years ago

TORONTO, March 30, 2023 (GLOBE NEWSWIRE) -- Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) announced today that…

Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

2 years ago

FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell…

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

2 years ago

— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with…